Trials / Completed
CompletedNCT00663195
Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure
Effects of Spironolactone on Circulating MMPs in Patients With Chronic Heart Failure
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Tottori University Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
The purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels and insulin resistance in patients with chronic heart failure.
Detailed description
Myocardial fibrosis is observed in failing hearts. MMPs are considered markers of fibrosis. Recently, circulating MMPs can be measured and are elevated in patients with chronic heart failure (CHF). It has been reported that spironolactone improves myocardial fibrosis in CHF animal models. Therefore, the purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels in patients with chronic heart failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | spironolactone + furosemide | spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks |
Timeline
- Start date
- 2004-01-01
- Completion
- 2005-12-01
- First posted
- 2008-04-22
- Last updated
- 2008-04-22
Source: ClinicalTrials.gov record NCT00663195. Inclusion in this directory is not an endorsement.